Header Logo

Simiso

Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hill A, Tovar Sanchez T, Delaporte E, Sokhela S, Simmons B, Kouanfack C, Mccann K, Levi J, Fairhead C, Venter F. Low CD4 counts predict excessive weight gains during first-line treatment for HIV. J Antimicrob Chemother. 2024 Sep 03; 79(9):2369-2378. PMID: 39028639.
      Citations:    Fields:    
    2. Venter WDF, Gandhi M, Sokhela S, Sikwese K, Bygrave H, Gama LD, Mphothulo N, Jamieson L, Siedner MJ, Pozniak A, Rojo P, Baptiste SL, Wambui J, Meyer-Rath G, Honerman B, Warren M, Gayle-Bekker L, Sinxadi P, Collins S, Burry J, M?ller K, Clayden P, Owen A, Hill A. The long wait for long-acting HIV prevention and treatment formulations. Lancet HIV. 2024 Aug 16. PMID: 39159655.
      Citations:    Fields:    
    3. Masuku SD, Brennan AT, Vetter B, Venter F, Mtshazo B, Sokhela S, Mashabane N, Kao K, Meyer-Rath G. The cost of adding rapid screening for diabetes, hypertension, and COVID-19 to COVID-19 vaccination queues in Johannesburg, South Africa. BMC Public Health. 2024 Jul 16; 24(1):1900. PMID: 39014354; PMCID: PMC11251297.
      Citations:    Fields:    Translation:HumansPHPublic Health
    4. Manne-Goehler J, Fabian J, Sokhela S, Akpomiemie G, Rahim N, Lalla-Edward ST, Brennan AT, Siedner MJ, Hill A, Venter WDF. Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa. J Int AIDS Soc. 2024 Jul; 27(7):e26268. PMID: 38978403; PMCID: PMC11231445.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    5. Kityo C, Mambule IK, Musaazi J, Sokhela S, Mugerwa H, Ategeka G, Cresswell F, Siika A, Kosgei J, Shah R, Naidoo L, Opiyo K, Otike C, M?ller K, Kaimal A, Wambui C, Van Eygen V, Mohammed P, Addo Boateng F, Paton NI, CARES trial team. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial. Lancet Infect Dis. 2024 May 28. PMID: 38821073.
      Citations: 1     Fields:    
    6. Mambule I, Norcross C, Achieng Ombajo L, Sokhela S, Laker Odongpiny EA, Owarwo N, Lawrence DS, Ruzagira E, Cresswell FV. Two-drug regimens for the treatment of HIV in Africa. Lancet HIV. 2024 Jun; 11(6):e419-e426. PMID: 38697180.
      Citations:    Fields:    Translation:Humans
    7. Mpofu R, Kawuma AN, Wasmann RE, Akpomiemie G, Chandiwana N, Sokhela SM, Moorhouse M, Venter WDF, Denti P, Wiesner L, Post FA, Haas DW, Maartens G, Sinxadi P. Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa. Br J Clin Pharmacol. 2024 May; 90(5):1247-1257. PMID: 38332460.
      Citations:    Fields:    Translation:HumansCells
    8. Sokhela S, Venter WDF, Bosch B, Woods J, McCann K, Akpomiemie G, Chandiwana N, Mashabane N, Tembo A, Simmons B, Lalla-Edward S, Siedner MJ, Sinxadi P, Hermans L, Fairlie L, Vos A, Abrams E, Manne-Goehler JM, Moorhouse M, Clayden P, Norris S, Qavi A, Chersich M, Masenya M, Arulappan N, Hill A. Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens. Open Forum Infect Dis. 2024 Mar; 11(3):ofae007. PMID: 38529213; PMCID: PMC10962246.
      Citations: 1     
    9. Brennan AT, Vetter B, Masuku SD, Mtshazo B, Mashabane N, Sokhela S, Venter WD, Kao K, Meyer-Rath G. Integration of point-of-care screening for type 2 diabetes mellitus and hypertension into the COVID-19 vaccine programme in Johannesburg, South Africa. BMC Public Health. 2023 11 20; 23(1):2291. PMID: 37986070; PMCID: PMC10662646.
      Citations:    Fields:    Translation:HumansPHPublic Health
    10. Masuku SD, Brennan AT, Vetter B, Venter F, Mtshazo B, Sokhela S, Mashabane N, Kao K, Meyer-Rath G. The cost of adding rapid screening for diabetes, hypertension, and COVID-19 to COVID-19 vaccination queues in Johannesburg, South Africa. Res Sq. 2023 Oct 10. PMID: 37886557; PMCID: PMC10602052.
      Citations:    
    11. Tovar Sanchez T, Mpoudi-Etame M, Kouanfack C, Delaporte E, Calmy A, Venter F, Sokhela S, Bosch B, Akpomiemie G, Tembo A, Pepperrell T, Simmons B, Casas CP, McCann K, Mirchandani M, Hill A. Risks of metabolic syndrome in the ADVANCE and NAMSAL trials. Front Reprod Health. 2023; 5:1133556. PMID: 37791109; PMCID: PMC10544962.
      Citations: 1     
    12. Mateza S, Bradford Y, Maartens G, Sokhela S, Chandiwana NC, Venter WDF, Post FA, Ritchie MD, Haas DW, Sinxadi P. Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans. Pharmacogenet Genomics. 2023 07 01; 33(5):91-100. PMID: 37099271; PMCID: PMC10234323.
      Citations:    Fields:    Translation:Humans
    13. Bosch B, Akpomiemie G, Chandiwana N, Sokhela S, Hill A, McCann K, Qavi A, Mirchandani M, Venter WDF. Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG. Clin Infect Dis. 2023 04 17; 76(8):1492-1495. PMID: 36519389.
      Citations: 13     Fields:    Translation:Humans
    14. Kawuma AN, Wasmann RE, Sinxadi P, Sokhela SM, Chandiwana N, Venter WDF, Wiesner L, Maartens G, Denti P. Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population. CPT Pharmacometrics Syst Pharmacol. 2023 06; 12(6):821-830. PMID: 37013631; PMCID: PMC10272303.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    15. Cindi Z, Kawuma AN, Maartens G, Bradford Y, Sokhela S, Chandiwana N, Venter WDF, Wasmann RE, Denti P, Wiesner L, Ritchie MD, Haas DW, Sinxadi P. Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV. Pharmacogenet Genomics. 2023 06 01; 33(4):79-87. PMID: 37098852; PMCID: PMC10154044.
      Citations:    Fields:    Translation:Humans
    16. Steegen K, Chandiwana N, Sokhela S, Venter WDF, Hans L. Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries. AIDS. 2023 05 01; 37(6):1009-1011. PMID: 36779485; PMCID: PMC10090297.
      Citations: 3     Fields:    Translation:HumansCells
    17. Sokhela S, Lalla-Edward S, Siedner MJ, Majam M, Venter WDF. Roadmap for Achieving Universal Antiretroviral Treatment. Annu Rev Pharmacol Toxicol. 2023 01 20; 63:99-117. PMID: 36662580; PMCID: PMC10807407.
      Citations: 1     Fields:    Translation:Humans
    18. Sokhela S, Bosch B, Hill A, Simmons B, Woods J, Johnstone H, Madhi S, Qavi A, Ellis L, Akpomiemie G, Bhaskar E, Levi J, Falconer J, Mirchandani M, Perez Casas C, Moller K, Pilkington V, Pepperrell T, Venter WDF. Comparing Prospective Incident Severe Acute Respiratory Syndrome Coronavirus 2 Infection Rates During Successive Waves of Delta and Omicron in Johannesburg, South Africa. Open Forum Infect Dis. 2022 Dec; 9(12):ofac587. PMID: 36540387; PMCID: PMC9757672.
      Citations:    
    19. Mondleki E, Banda CG, Chandiwana NC, Sokhela S, Wiesner L, Venter F, Maartens G, Sinxadi PZ. Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV. South Afr J HIV Med. 2022; 23(1):1452. PMID: 36751628; PMCID: PMC9772744.
      Citations: 4     
    20. Venter F, Sokhela S, Calmy A, Siedner MJ, Khoo S, Clayden P, Mkhondwane L, Bosch B, Chandiwana N, Hill A, Marconi VC, Boffito M, Sekwese K, Ali M, Delaporte E, Pozniak A, Mashabane N, Lalla-Edwards S, Carman M, Collins S. Response to comments by Taramasso and colleagues on weight gain stopping/switch rules for antiretroviral clinical trials. AIDS. 2022 11 01; 36(13):1900-1901. PMID: 36172876.
      Citations:    Fields:    
    21. Griesel R, Sinxadi P, Kawuma A, Joska J, Sokhela S, Akpomiemie G, Venter F, Denti P, Haas DW, Maartens G. Pharmacokinetic and pharmacogenetic associations with dolutegravir neuropsychiatric adverse events in an African population. J Antimicrob Chemother. 2022 10 28; 77(11):3110-3117. PMID: 36031789; PMCID: PMC7613765.
      Citations:    Fields:    Translation:Humans
    22. May AK, Seymour H, Etheredge H, Maher H, Nunes MC, Madhi SA, Sokhela SM, Venter WDF, Martinson N, Nabeemeeah F, Cohen C, Moyes J, Walaza S, Tempia S, Kleynhans J, von Gottberg A, Nel J, Dawood H, Variava E, Tollman S, Kahn K, Herbst K, Wong EB, Tiemessen CT, van Blydenstein A, Murray L, Venter M, Fabian J, Ramsay M. Coronavirus Host Genomics Study: South Africa (COVIGen-SA). Glob Health Epidemiol Genom. 2022; 2022:7405349. PMID: 36263375; PMCID: PMC9560830.
      Citations:    Fields:    Translation:HumansCells
    23. Sokhela S, Bosch B, Hill A, Simmons B, Woods J, Johnstone H, Akpomiemie G, Ellis L, Owen A, Casas CP, Venter WDF. Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection. J Antimicrob Chemother. 2022 09 30; 77(10):2706-2712. PMID: 35953881; PMCID: PMC9384711.
      Citations: 3     Fields:    Translation:HumansCells
    24. Venter WDF, Sokhela S, Nel J. Integrase inhibitors hand us a new HIV clinical puzzle. Lancet HIV. 2022 Jun 07. PMID: 35688165.
      Citations: 2     Fields:    Translation:Humans
    25. Cindi Z, Kawuma AN, Maartens G, Bradford Y, Venter F, Sokhela S, Chandiwana N, Wasmann RE, Denti P, Wiesner L, Ritchie MD, Haas DW, Sinxadi P. Pharmacogenetics of dolutegravir plasma exposure among Southern Africans living with HIV. J Infect Dis. 2022 May 04. PMID: 35512135.
      Citations: 1     Fields:    Translation:HumansCells
    26. Griesel R, Maartens G, Chirehwa M, Sokhela S, Akpomiemie G, Moorhouse M, Venter F, Sinxadi P. Corrigendum to: CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. Clin Infect Dis. 2022 Mar 01; 74(4):755. PMID: 35099526; PMCID: PMC8886893.
      Citations:    Fields:    
    27. Griesel R, Kawuma AN, Wasmann R, Sokhela S, Akpomiemie G, Venter WDF, Wiesner L, Denti P, Sinxadi P, Maartens G. Concentration-response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy. Br J Clin Pharmacol. 2022 03; 88(3):883-893. PMID: 34954840; PMCID: PMC7612404.
      Citations: 7     Fields:    Translation:Humans
    28. Jamieson L, Serenata C, Makhubele L, Sokhela S, Mashabane N, Akpomiemie G, Johnson LF, Venter WDF, Meyer-Rath G. Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial. AIDS. 2021 12 15; 35(Suppl 2):S173-S182. PMID: 34848584.
      Citations: 2     Fields:    Translation:Humans
    29. Venter WDF, Sokhela S, Calmy A, Mkhondwane L, Bosch B, Chandiwana N, Hill A, Sekwese K, Mashabane N, Pozniak A, Khoo S, Ali M, Delaporte E, Lalla-Edwards S, Clayden P, Marconi VC, Siedner MJ, Boffito M, Serenata C, Carman M, Collins S. Weight gain stopping/switch rules for antiretroviral clinical trials. AIDS. 2021 12 15; 35(Suppl 2):S183-S188. PMID: 34848585; PMCID: PMC8694575.
      Citations: 7     Fields:    Translation:Humans
    30. Asif S, Baxevanidi E, Hill A, Venter WDF, Fairlie L, Masenya M, Serenata C, Sokhela S, Chandiwana N. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz. AIDS. 2021 12 15; 35(Suppl 2):S117-S125. PMID: 34261099.
      Citations: 4     Fields:    Translation:Humans
    31. Griesel R, Maartens G, Chirehwa M, Sokhela S, Akpomiemie G, Moorhouse M, Venter F, Sinxadi P. CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. Clin Infect Dis. 2021 12 06; 73(11):e3902-e3909. PMID: 32960272; PMCID: PMC8653639.
      Citations: 26     Fields:    Translation:Humans
    32. Pepperrell T, Venter WDF, McCann K, Bosch B, Tibbatts M, Woods J, Sokhela S, Serenata C, Moorhouse M, Qavi A, Hill A. Participants on Dolutegravir Resuppress Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the ADVANCE Trial. Clin Infect Dis. 2021 08 16; 73(4):e1008-e1010. PMID: 34398955.
      Citations: 10     Fields:    Translation:HumansCells
    33. McCann K, Shah S, Hindley L, Hill A, Qavi A, Simmons B, Serenata C, Sokhela S, Venter WDF. Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. AIDS. 2021 08 01; 35(10):1657-1665. PMID: 33927086.
      Citations: 24     Fields:    Translation:Humans
    34. Cindi Z, Maartens G, Bradford Y, Venter WDF, Sokhela S, Chandiwana NC, Haas DW, Sinxadi P. Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens. J Acquir Immune Defic Syndr. 2021 07 01; 87(3):1002-1009. PMID: 33625064; PMCID: PMC8192425.
      Citations: 3     Fields:    Translation:HumansCells
    35. Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, Serenata C, Akpomiemie G, Masenya M, Qavi A, Chandiwana N, McCann K, Norris S, Chersich M, Maartens G, Lalla-Edward S, Vos A, Clayden P, Abrams E, Arulappan N, Hill A. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020 10; 7(10):e666-e676. PMID: 33010240.
      Citations: 83     Fields:    Translation:HumansCellsCTClinical Trials
    36. Wadley AL, Venter WDF, Moorhouse M, Akpomiemie G, Serenata C, Hill A, Sokhela S, Mqamelo N, Kamerman PR. High individual pain variability in people living with HIV: A graphical analysis. Eur J Pain. 2021 01; 25(1):160-170. PMID: 32939898.
      Citations:    Fields:    Translation:Humans
    37. Pepperrell T, Hill A, Moorhouse M, Clayden P, McCann K, Sokhela S, Serenata C, Venter WDF. Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic. J Virus Erad. 2020 Apr 30; 6(2):70-73. PMID: 32405424; PMCID: PMC7213067.
      Citations: 8     
    38. Pepperrell T, Venter WDF, Moorhouse M, McCann K, Bosch B, Tibbatts M, Woods J, Sokhela S, Serenata C, Hill A. Time to rethink endpoints for new clinical trials of antiretrovirals? Long-term re-suppression of HIV RNA with integrase inhibitors. AIDS. 2020 02 01; 34(2):321-324. PMID: 31876594.
      Citations: 4     Fields:    Translation:HumansCells
    39. Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, Serenata C, Akpomiemie G, Qavi A, Chandiwana N, Norris S, Chersich M, Clayden P, Abrams E, Arulappan N, Vos A, McCann K, Simmons B, Hill A. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med. 2019 08 29; 381(9):803-815. PMID: 31339677.
      Citations: 266     Fields:    Translation:HumansCellsCTClinical Trials
    40. Venter WDF, Moorhouse M, Sokhela S, Serenata C, Akpomiemie G, Qavi A, Mashabane N, Arulappan N, Sim JW, Sinxadi PZ, Wiesner L, Maharaj E, Wallis C, Boyles T, Ripin D, Stacey S, Chitauri G, Hill A. Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial. Lancet HIV. 2019 07; 6(7):e428-e437. PMID: 31202690.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    41. Venter WDF, Kambugu A, Chersich MF, Becker S, Hill A, Arulappan N, Moorhouse M, Majam M, Akpomiemie G, Sokhela S, Poongulali S, Feldman C, Duncombe C, Ripin DHB, Vos A, Kumarasamy N. Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial. J Acquir Immune Defic Syndr. 2019 02 01; 80(2):224-233. PMID: 30640204; PMCID: PMC6358196.
      Citations: 10     Fields:    Translation:Humans
    42. Pepper DJ, Marais S, Wilkinson RJ, Bhaijee F, Maartens G, McIlleron H, De Azevedo V, Cox H, McDermid C, Sokhela S, Patel J, Meintjes G. Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors. BMC Infect Dis. 2010 Mar 30; 10:83. PMID: 20353569; PMCID: PMC2858733.
      Citations: 15     Fields:    Translation:HumansCells
    Sokhela's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (109)
    Explore
    _
    Co-Authors (24)
    Explore
    _
    Similar People (60)
    Explore
    _